Latest Conference Articles

Conference Coverage From the 2012 ESMO Congress

Coverage from the 2012 European Society for Medical Oncology congress, held at the Austria Center Vienna from September 28 - October 2, in Vienna, Austria.

Dr. Spigel Discusses the Evolving NSCLC Treatment Landscape

Dr. David Spigel, from the Sarah Cannon Research Institute, discusses the rapidly evolving non-small cell lung cancer treatment landscape.

Dr. Reckamp Evaluates the Predictive Efficacy of VeriStrat

Dr. Karen Reckamp, from City of Hope, evaluates the predictive efficacy of the pretreatment serum test VeriStrat for non-small cell lung cancer.

Targeted Therapy Combination Slows NSCLC

Patients with refractory non-small cell lung cancer had a statistically significant improvement in PFS when treated with targeted therapy duo versus a single agent.

Mutation Confers Anti-EGFR Resistance

A common mutation in NSCLC confers resistance to tyrosine kinase inhibitors and worsens survival, creating a need for an alternative approach to treating the subgroup of patients with the mutation.

Hint of Survival Benefit in NSCLC With Bavituximab Plus Docetaxel

Patients with advanced non-small cell lung cancer lived twice as long when they received an indirect angiogenesis inhibitor plus docetaxel instead of docetaxel alone.

The 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology

A brief introduction to the topics and focus of the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.

Dr. Crawford on Managing Febrile Neutropenia

Jeffrey Crawford, MD, from Duke University Medical Center, on Managing Febrile Neutropenia.

Photos From the 2012 MASCC/ISOO Symposium

A compilation of photos from the 2012 combined conferences of the Multinational Association of Supportive Care in Cancer (MASCC) and the International Society of Oral Oncology (ISOO).

Dr. Holland on the Stigma Toward Psychosocial Care

Dr. Jimmie Holland, from Memorial Sloan-Kettering Cancer Center, on the Stigma Toward Psychosocial Care.

Diarrhea Less Severe With Molecularly Targeted Agents Than With Standard Chemotherapy

Recent evidence shows that some of the newer molecularly targeted therapies can cause diarrhea, which can lead to dose reductions and alterations.

Targeted Therapies Safer for Heart Than Anthracyclines

Although molecularly targeted agents can cause cardiac damage, it appears to be reversible and related to cellular dysfunction, as distinct from agents such as anthracyclines that cause cellular death and irreversible cardiac dysfunction.

Dr. Gralla on Chemotherapy-Induced Nausea and Vomiting

Dr. Richard Gralla, from the Quality of Life Research Associates, on Chemotherapy-Induced Nausea and Vomiting.

Dr. Foley Discusses Guidelines for Cancer Pain Management

Dr. Kathleen Foley, from Memorial Sloan-Kettering Cancer Center, Discusses the World Health Organization Guidelines for Cancer Pain Management.

Dr. Grunberg Describes the MASCC International Symposium

Dr. Steven Grunberg, from the Vermont Cancer Center, Describes the 2012 Multinational Association of Supportive Care in Cancer Symposium.

Despite Progress, Complete Control of Chemotherapy-Induced Nausea Lags Behind Vomiting Control

Control of chemotherapy-induced nausea and vomiting (CINV) has come a long way in the past 30 years. Thirty years ago, about 10% of patients had complete control of emesis; in the 1990s about 50% had complete control. Today about 85% of patients treated with highly emetogenic chemotherapy have complete control of emesis.

Three Decades of Progress in Treating Febrile Neutropenia

Treatment of febrile neutropenia (FN) has dramatically improved over the past 3 decades, but there is room for improvement, according to Jean Klastersky, MD, Institut Jules Bordet, Brussels, Belgium.

ASCO President Recaps Top Stories From Meeting

Dr. Michael P. Link, ASCO President, from Stanford University School of Medicine, on the top stories from the 2012 ASCO Annual Meeting.

2012 ASCO Annual Meeting Slideshow

Photos taken at the 2012 ASCO Annual Meeting held at the McCormick Place in Chicago, Illinois, from June 1-5, 2012.

Dr. Wood on Family Histories and Genetic Counseling

Dr. Marie Wood, from the University of Vermont, on Family Histories and Genetic Counseling for Breast and Colorectal Cancers.

Two Newer Breast Cancer Therapies Not Superior to Standard Paclitaxel, Study Suggests

The newer and more expensive breast cancer treatments nab-paclitaxel and ixabepilone, failed to demonstrate superior efficacy versus standard care with weekly paclitaxel.

Study Finds Cymbalta Reduces Peripheral Neuropathy Pain

The antidepressant duloxetine relieved pain associated with chemotherapy-induced peripheral neuropathy for 59% of patients.

Pilot Study Evaluates a Proposed Quality Measure for Family History Collection and Genetic Testing Referral

Only half of those with breast cancer and one-quarter of those with colon cancer were referred for genetic counseling or testing by their physicians.

FDA and Industry Collaborating to Prevent Cancer Drug Shortages

Drug manufacturers are working with the FDA to report anticipated shortages earlier and ensure alternative sources of needed drugs are available.

Dr. Rugo on Paclitaxel Superiority in Advanced Breast Cancer

Dr. Hope Rugo, from the UCSK Comprehensive Cancer Center, on the First-line Superiority of Paclitaxel for Advanced Breast Cancer.

Two New BRAF-Targeted Therapies Reduce Disease Progression in Advanced Melanoma Patients

Trametinib and dabrafenib delayed disease progression and showed a trend toward improved survival in patients with advanced melanoma.

Dr. Robert on the Trametinib METRIC Trial Results

Dr. Caroline Robert, from the Institute Gustave Roussy in Paris, France, Discusses the MEK Inhibitor, Trametinib, METRIC Trial Results.

Dr. Demetri Discusses Regorafenib for GIST Patients

Dr. George Demetri, from Dana-Farber Cancer Institute, Discusses Regorafenib for Patients with GIST Trial Results.

Regorafenib Offers New Hope for Patients With Treatment-Resistant GIST

The oral multikinase inhibitor regorafenib reduced the risk of disease progression by 73% in patients with gastrointestinal stromal tumors who had exhausted all other treatment options.

Afatinib Prolongs PFS in Lung Cancer Trial

Afatinib markedly prolonged PFS compared with standard chemotherapy in patients with advanced lung adenocarcinomas that tested positive for EGFR mutations, particularly one of two common mutation types.